Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 31Neoplasms 18Kidney Neoplasms 17Neuroendocrine Tumors 16Neoplasm Metastasis 13Tuberous Sclerosis 10Prostatic Neoplasms 8Carcinoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Glioma 7Glioblastoma 7Astrocytoma 7Waldenstrom Macroglobulinemia 6Triple Negative Breast Neoplasms 6Recurrence 6Lymphoma 6Head and Neck Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Carcinoma, Neuroendocrine 5Brain Neoplasms 5Sezary Syndrome 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Mycosis Fungoides 4

Interventions

imetelstat 1entinostat 1GRN163L peptide 1Everolimus 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Stem Neoplasms × Everolimus × Clear all
NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
CNS

Glioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡